伽玛刀治疗分泌型垂体腺瘤120例分析  

Gamma knife for hypersecreting pituitary adenom:analysis of 120 cases

作　　者：袁玉会[1] 董欣明[1] 于宏伟[1] 关俊宏[1] 王成林[1] 

机构地区：[1]中国医科大学附属第二医院神经外科,沈阳110004

出　　处：《中华外科杂志》2006年第6期416-419,共4页Chinese Journal of Surgery

摘　　要：目的评价伽玛刀作为首选方法治疗分泌型垂体腺瘤的疗效。方法回顾性分析1995年7月至2003年12月应用伽玛刀作为首选治疗120例分泌型垂体瘤患者的临床资料。治疗等剂量曲线45％～70％、周边剂量15～32Gy（平均28．5Gy），中心剂量为35～70Gy（平均45．5Gy），靶点165个（平均1～3个）。结果120例患者中111例获得随访，随访时间12～72个月，平均36个月。随访病例内分泌激素水平控制率为48．6％；肿瘤生长控制率96．2％；垂体功能低下发生率为2．7％；肿瘤卒中发生率0．9％。结论伽玛刀作为首选治疗分泌型垂体腺瘤安全、有效，肿瘤生长控制良好。Objective To estimate the efficacy of Gamma knife radiosurgery（GKR） especially as a primary surgical treatment for hypersecreting pituitary adenoma. Methods One hundred and twenty cases with hypersecreting pituitary adenoma had been treated by Gamma knife radiosurgery. The clinical date had been analysed retrospectively. The tumor margin was covered by an isodose ranging from 45% to 70%. The margin dose was 15 to 32 Gy （ mean 28.5 Gy） and the maximum dose varied from 35 to 70 Gy （ mean 45.5 Gy）. The total number of isocenter was 165 （ mean 1-3 ）. Results One hundred and eleven cases had been followed-up by hormone level, and 104 cases had been followed-up by image of MRI. The mean follow-up duration was 12-72 months（ mean 36 months）. The control rate of hormone level was 48.6%, the control rate of tumor growth was 96.2%, the incidence of hypopituitarism was in 2.7% and the incidence of tumor apoplexy was in 0. 9% in followed-up cases. Conclusions As a primary surgical treatment for hypersecreting pituitary adenoma, GKR can be effective and safe in controlling tumor growth and inducing hormonal normalization.

关 键 词：催乳素瘤 放射外科手术 伽玛刀 

分 类 号：R736.4[医药卫生—肿瘤]